Trulicity ® (dulaglutide)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).

Can multiple Trulicity® (dulaglutide) injections be used to make a larger dose?

Lilly does not recommend using multiple dulaglutide injections to make a larger dose. Multiple injections of lower doses were studied in a phase 2 study as part of the development of higher doses but combining multiple dose injections is not recommended.

UK_cFAQ_GLP070_COMBINING_INJECTIONS
UK_cFAQ_GLP070_COMBINING_INJECTIONS
en-GB

Administering Multiple Injections

Administering multiple injections of dulaglutide has not been tested in a phase 3 clinical study, so there is limited evidence to support the efficacy and safety of administering multiple injections to create a higher dose. Using multiple dulaglutide injections is not captured in the Summary of Product Characteristics; therefore, Eli Lilly and Company does not recommend using multiple lower dose injections.1,2

Combining Injections in a Phase 2 Study

The phase 2 study, GBGJ, compared dulaglutide 1.5 mg, 3.0 mg, and 4.5 mg with placebo. Patients randomized to dulaglutide 3.0 mg received two 1.5 mg doses, and patients randomized to dulaglutide 4.5 mg dose received three 1.5 mg doses.1,3

Efficacy and safety results of this phase 2 trial led to further development and completeness of the phase 3 study, AWARD-11, which was the basis for the approval of the higher doses.1

Even though this phase 2 study did use multiple injections of dulaglutide 1.5 mg, this was not done in the phase 3 registration study, so Eli Lilly and Company does not recommend combining multiple dose injections based on the approved dosing of dulaglutide.2,3

References

1Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2Trulicity [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

3Frias JP, Wynne AG, Matyjaszek-Matuszek B, et al. Efficacy and safety of an expanded dulaglutide dose range: a phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin. Diabetes Obes Metab. 2019;21(9):2048-2057. https://doi.org/10.1111/dom.13764

Date of Last Review: 14 January 2022


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request